What are the common and uncommon side effects of mRNA (messenger ribonucleic acid) vaccines?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Common and Uncommon Side Effects of mRNA Vaccines

mRNA COVID-19 vaccines commonly cause mild to moderate side effects that typically resolve within a few days, with injection site reactions and fatigue being the most frequently reported effects. The safety profile of these vaccines shows a favorable benefit-to-risk ratio across all age groups, with serious adverse events being rare.

Common Side Effects

Local Reactions

  • Injection site reactions (84.1%) - most common local side effect 1, 2
  • Pain at injection site (66.2% after dose 1,68.6% after dose 2) 3
  • Local swelling or redness

Systemic Reactions

  • Fatigue (62.9%) - second most common side effect 1, 2, 3
  • Headache (55.1%) 1, 2, 3
  • Muscle pain/myalgia (38.3%) 1, 2
  • Chills (31.9%) 1, 2
  • Joint pain (23.6%) 1, 2
  • Fever (14.2%) 1, 2

Timing and Severity

  • Side effects are generally more pronounced after the second dose 2, 3
  • Most reactions are mild to moderate in severity 3
  • Reactogenicity peaks within 24 hours after vaccination 3
  • Most symptoms resolve within 2-3 days 2
  • Approximately 32.1% of recipients report being unable to perform normal activities or work after dose 2 (compared to 11.9% after dose 1) 3
  • Less than 1% of vaccine recipients seek medical care for side effects 3

Uncommon Side Effects

Rare Cardiovascular Effects

  • Myocarditis and pericarditis - primarily in adolescent and young adult males 1
    • For every 1 million males aged 12-29 years receiving a second dose, approximately 39-47 cases of myocarditis would be expected 1
    • Risk after booster doses appears similar to or lower than after dose 2 1
    • The risk may differ between the two mRNA vaccines, with higher rates observed with the Moderna (mRNA-1273) vaccine 1

Neurological Effects

  • Bell's palsy - reported in clinical trials at a rate of 4 cases in the Pfizer vaccine group vs. 0 in placebo 1, 4
  • Theoretical concerns exist about potential neurological effects in patients with pre-existing conditions 1

Lymphatic System

  • Local lymphadenopathy: 1.1% in vaccine recipients vs. 0.63% in placebo 1

Hypersensitivity Reactions

  • Hypersensitivity: 1.5% in vaccine recipients vs. 1.1% in placebo 1

Benefit-Risk Assessment

Despite the potential side effects, the benefit-risk ratio strongly favors vaccination. For every 1 million males aged 12-29 years (highest risk group for myocarditis) receiving a second dose:

  • 39-47 cases of myocarditis would be expected
  • But vaccination would prevent:
    • 560 hospitalizations
    • 138 ICU admissions
    • 6 deaths 1, 2

Management of Side Effects

  • For typical post-vaccination symptoms (pain, fever, headache):

    • Simple analgesics (acetaminophen, NSAIDs)
    • Adequate hydration
    • Rest as needed 2
  • Red flag symptoms requiring immediate medical attention:

    • Severe headache with onset 5-30 days after vaccination
    • Headache that worsens when lying down
    • Visual disturbances, speech difficulties
    • Unexplained bruising or bleeding
    • Chest pain, shortness of breath 2

Special Populations

  • Patients with psychiatric disorders may be at higher risk for COVID-19 complications and should be prioritized for vaccination 1
  • Patients with neurological disorders (MS, myasthenia gravis, Guillain-Barré syndrome) can generally receive mRNA vaccines safely 1
  • Cancer patients and transplant recipients may have reduced immune response but similar side effect profiles 1, 2

The large-scale surveillance data from over 298 million doses of mRNA COVID-19 vaccines administered in the first 6 months of the US vaccination program confirms that most reported adverse events were mild and short in duration 3, with mRNA-based vaccines showing higher efficacy against SARS-CoV-2 than other vaccine platforms 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.